Vaccine breakthrough stops cancer returning in trial

A new jab extended the length of time patients were cancer free, but it is unclear for how long.

Moderna Surges as Stocks Rise & Long-Term Yields Retreat | Closing Bell

Comprehensive cross-platform coverage of the U.S. market close on Bloomberg Television, Bloomberg Radio, and YouTube with Romaine Bostick, Isabelle Lee, Carol Massar and Emily Graffeo. (Source: Bloomberg)

Moderna, Merck Say mRNA Vaccine Prevents Melanoma From Returning

The companies say the vaccine prevented the return and spread of the cancer in high-risk melanoma patients.

By Carolyn Y. Johnson

Moderna’s cancer shot: exciting for investors, inconclusive for patients

A glimmer of hope for sufferers, a potential revenue platform for a cash-burner, and a whole heap of unknowns

Real-world study of Oregon's nonmedical psilocybin program shows promise

Oregon was the first state to establish a legalized and regulated psilocybin industry. Since then, thousands have tried magic mushrooms. Here is the first data from the state's real life experiment.

By Will Stone

Moderna, Merck unveil mRNA-based cancer vaccine that cuts spread

Moderna's mRNA vaccine Intismeran shows promise, reducing melanoma recurrence and spread in late-stage trials.

Kai Trump reveals how family rallied around mom Vanessa amid breast cancer battle: ‘It’s a long journey’

Kai Trump opens up about how her family rallied around mom Vanessa during breast cancer treatment and the new initiative that grew from her diagnosis.

Merck and Moderna say mRNA melanoma vaccine hits goals in late-stage trial

Merck and Moderna report that a personalized mRNA vaccine helped prevent skin cancer from returning in high-risk patients. Observers greeted the news with enthusiasm but noted that full data from the ongoing late-stage study has yet to be released.

Merck, Moderna claim encouraging melanoma vaccine trial results

US pharmaceutical firms Merck and Moderna announced on Wednesday encouraging results from a trial of their experimental vaccine against melanoma, potentially clearing the way for approval. The vaccine, called intismeran autogene, showed “statistically significant and clinically meaningful improvements” for skin cancer patients when used with Merck’s Keytruda treatment, the companies said in a statement. Unlike conventional vaccines, so-called therapeutic vaccines like intismeran treat rather...

By Agence France-Presse

Moderna shares surge as melanoma vaccine with Merck succeeds in large trial

Interim analysis ​shows goals were met for recurrence and preventing cancer spread

By Michael Erman and Julie Steenhuysen

Moderna’s cancer-vaccine breakthrough drives broad biopharma stock rally

The biopharmaceutical sector has struggled with a prolonged downturn in recent years but has been on an upswing of late.

By Jaimy Lee

Moderna Shares Skyrocket 95% Toward Best Day Ever—On Success Of Cancer Drug Trial

The trial marked the first successful final-stage study for any mRNA-based cancer therapy.

By Ty Roush, Forbes Staff

Moderna’s and Merck’s personalized mRNA vaccine shows real promise against deadly skin cancer melanoma in late stage trial and sends stocks soaring

The shot, paired with Merck's Keytruda, cut the risk of melanoma recurrence in a trial of more than 1,100 patients.

By Catherina Gioino

Moderna shares soar 135% in a day after cancer vaccine succeeds in late-stage trial

Moderna shares surged after its personalized mRNA cancer vaccine trial showed positive results. The treatment, combined with Keytruda, reduced melanoma recurrence and spread significantly. This marks the first successful late-stage trial for an mRNA cancer vaccine. The findings offer hope for future growth beyond COVID-19 vaccines. Discussions with regulators are expected within the next few months.

Moderna stock jumps 120% after cancer vaccine trial win: What investors need to know

Moderna stock surged after its mRNA cancer vaccine showed positive Phase 3 results with Merck’s Keytruda, boosting hopes for a new melanoma treatment.

Fears of skin cancer surge after heatwave-related sunburns

Concern Irish skin cancer cases could double by 2040

By Ralph Riegel

Biotechs hit a post-pandemic high after mRNA trial win for Moderna, Merck

Moderna shares jump 60% on melanoma vaccine trial

Shares in pharma giant Moderna soared about 60% in premarket trading after the company, in a joint statement with Merck, said its mRNA vaccine, combined with Merck's immunothe...

Holy Grail In Cancer Treatment? Moderna Erupts After Melanoma Vaccine Late-Stage Trial Success

Holy Grail In Cancer Treatment? Moderna Erupts After Melanoma Vaccine Late-Stage Trial Success Moderna's shares soared as much as 83% in premarket trading in New York after its personalized cancer vaccine, developed in collaboration with Merck & Co., reduced the risk of melanoma returning in a large, late-stage trial. The result marks the first positive Phase 3 trial for a personalized cancer vaccine by any company.  The study met its primary endpoint by showing that the cancer ...

By Tyler Durden